Also from 2001 Annual Report...
"In 2002, we will expand clinical trials with Endostatin, Panzem and Angiostatin."
Your message hasn't changed, but clearly other things have changed. Today we have not just this promise from Holaday and Gubish of expanded trials, but actual trials, lots of them.
We have the addition to the knowlege base of the hundreds of studies on 2me2 since 2001, studies that George so kindly finds and posts for us here. We have Avastin, an angiogensis inhibitor approved by the FDA as proof that this is all not just science fiction-even TV docs like House are talking about angiogenesis inhibitors.
This last dilution was about 12 1/2 per cent, at a buck sixty and change, it would not be that costly to undilute. They will get the money. You might not like how they get it, but they will get it.
Market Data 
Markets 
AI
